Evidence map›Paper›PMID 33650673›Full record

ArticleOncology reports2021

LINC00665 functions as a competitive endogenous RNA to regulate AGTR1 expression by sponging miR‑34a‑5p in glioma.

Yongyue Dai, Yucheng Zhang, Maolin Hao, Renwu Zhu

RetractedOpen access · hybridAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. The Emerging Roles of LINC00665 in Human Cancers.Frontiers in cell and developmental biology · 2022
    Review
  11. Article
4 · The record

Corrections and comments

  • Retraction · 2024-07-08Author Unresponsive · Concerns/Issues about Data · Euphemisms for Plagiarism · Investigation by Journal/Publisher · Investigation by Third Party · Plagiarism of Data · · See also: https://pubpeer.com/publications/2375B16AACA729C7A113EE55299959
  • Retracted
5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Yongyue DaiDepartment of Pathophysiology, Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China.
Yucheng ZhangDepartment of General Surgery, Wenzhou Hospital Integrated Traditional Chinese and Western Medicine, Wenzhou, Zhejiang 325000, P.R. China.
Maolin HaoDepartment of Pathophysiology, Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China.
Renwu ZhuDepartment of General Surgery, Wenzhou Hospital Integrated Traditional Chinese and Western Medicine, Wenzhou, Zhejiang 325000, P.R. China.
Wenzhou Hospital of Traditional Chinese Medicine · CNWenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioma is the most aggressive tumor of the central nervous system. Long non‑coding RNAs (lncRNAs) may be involved in modulating tumor generation. The present study analyzed an lncRNA microarray of glioma and selected long intergenic non‑protein coding RNA 665 (LINC00665) as the research object. The mode of expression and biological function of LINC00665 in glioma were assessed using lncRNA microarray and RT‑qPCR analyses. Gain‑of‑function assays and/or loss‑of‑function assays were implemented to explore the role of LINC00665 in the progression of glioma. Dual‑luciferase reporter and RNA immunoprecipitation assays explored the downstream molecular mechanism of LINC00665. The function of the molecular pathway in progression of glioma was analyzed using rescue assays. High expression of LINC00665 was marked in glioma tissues and cells, which correlated with an unsatisfactory prognosis. Upregulation of LINC00665 significantly promoted the proliferation and invasion of glioma cells. LINC00665 acted as a competing endogenous RNA by sponging miR‑34a‑5p to upregulate angiotensin II receptor type 1 (AGTR1). LINC00665 promoted the progression of glioma by acting as a competitive endogenous RNA to competitively bind to miR‑34a‑5p and mediate AGTR1 expression.

Indexed as

AnimalsCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticGliomaHumansMaleMiceMicroRNAsMiddle AgedPrognosisReceptor, Angiotensin, Type 1RNA, Long NoncodingAGTR1 protein, humanMicroRNAsMIRN34 microRNA, humanReceptor, Angiotensin, Type 1RNA, Long Noncodingcell proliferationceRNAgliomaLINC00665miRNA

Identifiers

PMID33650673
PMCPMC7859982
OpenAlexW3123125880

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.